Randomized phase III trial of erlotinib versus docetaxel for patients with previously treated advanced non-small cell lung cancer.
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DELTA
- 02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 May 2014 Results published in the Journal of Clinical Oncology.
- 04 Jun 2013 Status changed from active, no longer recruiting to completed.